Ota Yu, Driscoll Julia, Hill Anneliese R, Yan Irene K, Patel Tushar
Department of Transplantation, Mayo Clinic, Jacksonville, FL, USA.
Cytometry and Cell Imaging Lab, Mayo Clinic, Jacksonville, FL, USA.
J Hepatocell Carcinoma. 2025 Aug 1;12:1677-1693. doi: 10.2147/JHC.S524341. eCollection 2025.
Emerging evidence links alterations in the tumor microbiome to therapeutic responses to immunotherapy. Alterations in β-catenin are among the most frequently observed oncogenic drivers of hepatocarcinogenesis and are associated with T-cell exclusion. However, their effect on the immune cell environment and microbiome in hepatocellular cancer is not well understood. We hypothesized that β-catenin could modulate the immune microenvironment through alterations in the secretome and release of extracellular vesicles (EV) that mediate tumor and immune cell interactions and increase tumor growth within regions with attenuated immune activity and reduced microbial diversity.
We used a synthetic transgenic murine model of β-catenin-driven hepatocarcinogenesis to analyze microbiome composition, diversity, and immune cell profiles in vivo. Tumor and stool samples were collected from mice with early- or late-stage hepatocellular carcinoma and were used for profiling.
The microbiome associated with intrahepatic tumors differs from that in non-tumoral regions, normal liver tissues, and gut tissues. Constitutive β-catenin expression modulates lipopolysaccharide-mediated signaling in macrophages and alters the secretion of immunomodulatory chemokines and cytokines. Tumoral immune cell profiles differed from those in hepatic tissues. EV-mediated signaling between immune cells and epithelial cells with mutant β-catenin and immune cells modulates immune cell populations in vitro and in vivo.
Mutations in β-catenin can drive immune responses through EV-based tumor cell-immune cell interactions to modulate both the tumor microflora and immune microenvironment. A potential strategy to augment responses to immunotherapy for hepatocellular cancer could target these interactions to restore microbial diversity or immune cell infiltration within the tumor microenvironment.
新出现的证据表明肿瘤微生物组的改变与免疫治疗的疗效相关。β-连环蛋白的改变是肝癌发生过程中最常观察到的致癌驱动因素之一,且与T细胞排除有关。然而,它们对肝细胞癌免疫细胞环境和微生物组的影响尚不清楚。我们推测,β-连环蛋白可通过分泌组的改变和细胞外囊泡(EV)的释放来调节免疫微环境,这些细胞外囊泡介导肿瘤与免疫细胞的相互作用,并在免疫活性减弱和微生物多样性降低的区域促进肿瘤生长。
我们使用β-连环蛋白驱动的肝癌发生的合成转基因小鼠模型,在体内分析微生物组组成、多样性和免疫细胞谱。从早期或晚期肝细胞癌小鼠中收集肿瘤和粪便样本,并用于分析。
与肝内肿瘤相关的微生物组不同于非肿瘤区域、正常肝组织和肠道组织中的微生物组。β-连环蛋白的组成性表达调节巨噬细胞中脂多糖介导的信号传导,并改变免疫调节趋化因子和细胞因子的分泌。肿瘤免疫细胞谱与肝组织中的不同。具有突变β-连环蛋白的免疫细胞与上皮细胞之间的EV介导信号传导以及免疫细胞在体外和体内调节免疫细胞群体。
β-连环蛋白突变可通过基于EV的肿瘤细胞-免疫细胞相互作用驱动免疫反应,从而调节肿瘤微生物群和免疫微环境。增强肝细胞癌免疫治疗反应的一种潜在策略可能是针对这些相互作用,以恢复肿瘤微环境中的微生物多样性或免疫细胞浸润。